Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer
- PMID: 15920165
- PMCID: PMC1602414
- DOI: 10.1016/S0002-9440(10)62490-X
Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer
Abstract
Hormonal therapy (androgen ablation and/or inhibition of androgen action) is the treatment of choice for advanced prostate cancer. After an initial response in most patients, tumors invariably progress to an androgen-independent state. It is unclear how prostate cancer cells proliferate without androgen. Recent studies suggest that interleukin-8 may promote androgen-independent proliferation, but the source of interleukin-8 in the prostate is unknown. Using immunohistochemistry, we show that interleukin-8 was expressed by the neuroendocrine tumor cells in human prostate cancer tissue. Expression of the interleukin-8 receptor CXCR1 was negative or low in benign prostatic tissue and was frequently increased in malignant cells of high-grade prostatic intraepithelial neoplasia and prostate cancer; however, CXCR1 was not detected in the neuroendocrine tumor cells, suggesting a paracrine mechanism by which interleukin-8 produced by neuroendocrine tumor cells stimulates androgen-independent proliferation of prostate cancer. Neuroendocrine tumor cells expressed another type of interleukin-8 receptor, CXCR2, suggesting an autocrine mechanism by which interleukin-8 regulates the differentiation or function of the neuroendocrine cells. These results, combined with previous reports that neuroendocrine differentiation is induced by hormonal therapy, suggest that neuroendocrine cells play an important role in promoting androgen-independent growth of prostate cancer through interleukin-8 signaling.
Figures





Similar articles
-
Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.Clin Cancer Res. 2005 Jun 1;11(11):4117-27. doi: 10.1158/1078-0432.CCR-04-1518. Clin Cancer Res. 2005. PMID: 15930347
-
Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.Oncogene. 2008 Jan 17;27(4):506-18. doi: 10.1038/sj.onc.1210656. Epub 2007 Jul 16. Oncogene. 2008. PMID: 17637748
-
Expression and role of Foxa proteins in prostate cancer.Prostate. 2006 Jul 1;66(10):1013-28. doi: 10.1002/pros.20299. Prostate. 2006. PMID: 16001449
-
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.Int J Clin Pract. 2006 Apr;60(4):462-70. doi: 10.1111/j.1742-1241.2006.00750.x. Int J Clin Pract. 2006. PMID: 16620361 Review.
-
Interleukin-6 regulation of prostate cancer cell growth.J Cell Biochem. 2005 Jun 1;95(3):497-505. doi: 10.1002/jcb.20477. J Cell Biochem. 2005. PMID: 15838876 Review.
Cited by
-
Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.J Pathol. 2023 May;260(1):43-55. doi: 10.1002/path.6063. Epub 2023 Mar 14. J Pathol. 2023. PMID: 36752189 Free PMC article.
-
Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30. Mol Cancer Res. 2012. PMID: 22290877 Free PMC article.
-
Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356. Epub 2009 Oct 6. Br J Cancer. 2009. PMID: 19809428 Free PMC article.
-
Senescence, apoptosis, and stem cell biology: the rationale for an expanded view of intracrine action.Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H893-901. doi: 10.1152/ajpheart.00414.2009. Epub 2009 Jul 10. Am J Physiol Heart Circ Physiol. 2009. PMID: 19592610 Free PMC article.
-
An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.Mol Biol Rep. 2021 Sep;48(9):6551-6561. doi: 10.1007/s11033-021-06648-8. Epub 2021 Aug 24. Mol Biol Rep. 2021. PMID: 34426905 Review.
References
-
- Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401–406. - PubMed
-
- Gregory CW, Johnson RT, Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892–2898. - PubMed
-
- Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60:132–139. - PubMed
-
- Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, DeVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997;11:450–459. - PubMed
-
- Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989;14:103–115. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical